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Abstract
Tumor microenvironment (TME) is an active player in carcinogenesis and changes in its composition modify cancer
growth. Carcinoma-associated fibroblasts, bone marrow-derived multipotent mesenchymal stem cells (BMMSCs),
and inflammatory cells can all affect the composition of TME leading to changes in proliferation, invasion and
metastasis formation of carcinoma cells. In this study, we confirmed an interaction between BMMSCs and oral
tongue squamous cell carcinoma (OTSCC) cells by analyzing the invasion progression and gene expression pattern.
In a 3-dimensional myoma organotypic invasion model the presence of BMMSCs inhibited the proliferation but
increased the invasion of OTSCC cells. Furthermore, the signals originating from OTSCC cells up-regulated the
expression of inflammatory chemokines by BMMSCs, whereas BMMSC products induced the expression of known
invasion linked molecules by carcinoma cells. Particularly, after the cell-cell interactions, the chemokine CCL5 was
abundantly secreted from BMMSCs and a function blocking antibody against CCL5 inhibited BMMSC enhanced
cancer invasion area. However, CCL5 blocking antibody did not inhibit the depth of invasion. Additionally, after
exposure to BMMSCs, the expression of type I collagen mRNA in OTSCC cells was markedly up-regulated.
Interestingly, also high expression of type I collagen N-terminal propeptide (PINP) in vivo correlated with the cancer-
specific mortality of OTSCC patients, whereas there was no association between cancer tissue CCL5 levels and the
clinical parameters. In conclusion, our results suggest that the interaction between BMMSC and carcinoma cells
induce cytokine and matrix molecule expression, of which high level of type I collagen production correlates with the
prognosis of OTSCC patients.
Citation: Salo S, Bitu C, Merkku K, Nyberg P, Bello IO, et al. (2013) Human Bone Marrow Mesenchymal Stem Cells Induce Collagen Production and
Tongue Cancer Invasion. PLoS ONE 8(10): e77692. doi:10.1371/journal.pone.0077692
Editor: Dimas Tadeu Covas, University of Sao Paulo - USP, Brazil
Received June 14, 2013; Accepted September 2, 2013; Published October 21, 2013
Copyright: © 2013 Salo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study has been supported by the Academy of Finland, the Finnish Cancer Society, the Sigrid Juselius Foundation, the Finnish Dental
Society Apollonia, and the Emil Aaltonen Foundation grants. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: tuula.salo@oulu.fi
☯ These authors contributed equally to this work.
Introduction
The tumor microenvironment (TME) undergoes extensive
changes during tumor growth [1] and the progression of a
tumor is dependent on stromal elements [2]. Cells in the
microenvironment, including carcinoma-associated fibroblasts
(CAFs), bone marrow-derived multipotent mesenchymal
stromal cells (BMMSCs), tumor associated macrophages
(TAMs) and other inflammatory cells as well as vascular cells
all contribute to varying degrees to the hallmarks of cancer and
cancer ecosystem [3] [4]. They produce extracellular matrix,
growth factors, cytokines, proteases and their regulators, and
thus, provide a microenvironment supporting cancer cell
proliferation and immortality, inducing angiogenesis,
reprogramming energy metabolism, evading immune
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destruction, and favoring invasion and metastasis [5],[1,3,6],
[4].
In tongue cancer the components of TME have an
elementary role in the invasion and metastasis processes with
a direct impact on patients’ clinical outcomes [7]. We have
shown that the high frequency of CAFs is associated with poor
prognosis in mobile tongue cancer patients [8], [9]. CAFs have
also been shown to localize at the site of metastatic lymph
node similarly to matched primary tongue tumors suggesting
facilitation of metastasis [10]. Our recent study profiled the
molecular cross-talk between oral cancer cells and TME and
presented that the examination of known pro-tumorigenic
components of the inflammatory infiltrate, such as regulatory T
cells, TAM2 (i.e. TAM subtype supporting invasion and
metastasis) cells, and regulatory T-cell inducing immune cells,
revealed negative impact for patients similar to CAFs [11].
BMMSCs have been shown to incorporate into damaged or
inflamed tissue as well as to home at tumors and the site of
metastasis where they integrate into the TEM and provide a
source for cells, such as CAFs [12], [13] [14], [15],, [2].
Cytokines and growth factors secreted by tumor cells together
with endocrine factors of inflammatory tissues surrounding
tumors attract BMMSCs to tumor stroma [16]. BMMSCs have
been shown to promote invasion and metastasis in various
cancers, such as breast, colon and lymphatic cancers [17],
[18], [19]. However, the impact and the role of BMMSCs in
TEM and the mechanisms of their potential effects on different
tumors still remain controversial [20], [21].
In addition to various cell types, the extracellular matrix
(ECM) proteins in TME can also act as crucial factors in
dynamic informational system influencing cancer outcome [22].
The most abundant protein in TME is type I collagen which
leads to the tumor growth, invasion and spreading of cancer.
Particularly, the release of the aminoterminal propeptide of type
I procollagen (PINP) indicates the tumor-induced fibro-
proliferative response [22-24].
The objective of this work was to investigate the effect of the
BMMSCs and carcinoma cells interactions on OTSCC gene
expression, invasion and clinical outcome of the OTSCC
patients. Here we demonstrated that BMMSCs induced
OTSCC carcinoma cell invasion in vitro partially through
chemokine CCL5 signaling since its inhibition reduced the
invasion area. In OTSCC cells the expression of type I collagen
mRNA was up-regulated by signals derived from BMSCC, and
the high expression level of immunoreactive type I procollagen
correlated with the cancer-specific mortality of the OTSCC
patients.
Materials and Methods
Cell culture
Human tongue squamous cell carcinoma cells HSC-3 (JCRB
0623; Osaka National Institute of Health Sciences, Osaka,
Japan), SAS (JCRB 0260; Osaka National Institute of Health
Sciences, Osaka, Japan) and human dysplastic oral
keratinocytes DOK (European Collection of Cell Cultures
94122104, Salisbury, Wilts., UK) were cultured in 1:1 DMEM/
F-12 (Invitrogen) supplemented with 100 U/ml penicillin, 100
µg/ml streptomycin, 50 µg/ml ascorbic acid, 250 ng/ml
fungizone, 5 µg/ml insulin (bovine pancreas), 0.4 µg/ml
hydrocortisone (all from Sigma-Aldrich), and 10% heat-
inactivated fetal bovine serum (FBS). For zymography, fetal
bovine serum was replaced by 0.5% lactalbumin (Sigma-
Aldrich). Human bone marrow-derived BMMSCs were originally
obtained from patients operated for hip fracture or
osteoarthritis. The ethical committee of Oulu University
Hospital had approved the study protocol (Statements
4/2000,58/2009 and 21/2011; Research Diary 180/2001 and
12/2004) and the patients had given their informed written
consent for participation in the study. The BMMSCs used in
this study were harvested and cultured as described previously
[25][26]. All experiments were carried out with cells with low
passage numbers 3 - 4. Human gingival fibroblasts (GF) used
in this study were obtained from biopsies of healthy gingiva as
described earlier [27]. Carcinoma-associated fibroblasts
(CaDEC12) [11]derived from a specimen of tongue SCC as
well as normal oral fibroblasts (NOFs) [28] were cultured in the
same media as GFs [27]. All cells were cultured in a humidified
atmosphere of 5% CO2 at 37°C. In BMMSC or GF co-cultures
with HSC-3, SAS or DOK cells BMMSC or GF culture media
was used.
Organotypic invasion assay
The organotypic invasion assay and the quantification of
invasion were performed as described previously [29]. In
monoculture assays 2.0 x 105 - 4 x 105 HSC-3 or SAS cells or 2
x 105 DOK cells were cultured on the top of myoma disk for 10
- 14 days. In co-culture assays 0.5 - 1.5 x 105 BMMSCs were
added together with cancer cells on the top of the myoma disks
(OTSCC:BMMSC ratio varied from 2:1 to 5:1). The histological
sections of myoma disks were stained with monoclonal
pancytokeratin antibody (DAKO, clone AE1/AE3). The average
of invasion area or depth of HSC-3, SAS, DOK or any other
control cells grown in monoculture was set as 100 %. For the
inhibition of invasion, 50 µg/ml of monoclonal antibody against
human CCL5 (R&D Systems, MAB678), CXCL1 (R&D
Systems, MAB275) or isotype matched mouse normal IgG
(Jackson Laboratories) were added to cell culture media.
Proliferation assays
Quantification of proliferation in the organotypic invasion
assay was performed from triplicate myoma disks per cell line
used. Histological sections cut from the disks representing
inner parts of the disk were immunostained with polyclonal
antibody against Ki67 (Abcam, #15580). Cell proliferation rate
was determined as the percentage of Ki67-expressing cells
among all cells per microscopic field in the cell layer on the top
of the myoma disk. Cancer cells were first labeled with
Vybrant® CM-DiI cell-tracking solution (Life Technologies) for
the discrimination of cancer cells from BMMSCs. Altogether
four microscopic fields were counted per section (12 fields per
sample). For the cell culture proliferation assay 2 x 104 HSC-3
cells were cultured as a monoculture or as a co-culture with 1 x
104 BMMSCs or GFs on four chamber slides (Lab-Tek) per test
for 24 h. The slides were stained with polyclonal antibody
against Ki67 and Alexa Fluor® 488 secondary antibody
Mesenchymal Stem Cells in Oral Tongue Carcinoma
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(Molecular Probes) and counterstained with DAPI. 10
microscopic fields per chamber slide were examined and cell
proliferation rate was determined as a percentage of Ki67-
expressing cells among all cells per microscopic field.
Scratch assay
A total of 1 x 105 HSC-3 cells and 1 x 105 BMMSCs or GFs
were co-cultured in 10% FCS complete culture media in 24-
well plates (Costar) in triplicate wells until confluence after
which a wound was made by using a pipet tip. The wells were
washed with cell culture media and the wounded areas were
photographed immediately after wounding (0 h) and again in
the end of the study (20 h) when cells were stained with crystal
violet. The size of the wound area and the closure of wound
were analyzed with ImageJ (version 1.45s, http://
imagej.nih.gov/ij/). The completely healed wound area was set
to a value 100.
Zymography
Zymography performed as previously described [29] was
used to detect the expression of metalloproteinases 2 and 9
(MMP-2 and -9) in HSC-3, SAS and DOK cell culture media
after o/n incubation with 100 ng/ml of recombinant CCL5
(rCCL5) (R&D Systems, #278-RN).
Microarray
HSC-3 cells were cultured as a monoculture or in a co-
culture with BMMSC cells (cell ratio 1:1) on 6-well plates in two
separate experiments for 24 h. Next HSC-3 cells were sorted
out from co-cultures with FACS (FACScan, Becton Dickinson).
RNA was extracted and purified from the cells with the Qiagen
RNeasy kit according to the manufacturer's instructions and
pooled for microarray.
In another set of co-culture assay, 80% confluent cultures of
HSC-3 were grown in HSC-3 media with 2% FBS for 24 h. The
media were collected, centrifuged, transferred to BMMSC
cultures and incubated for 24 h, after which the cells were
collected. RNA was extracted as described above from three
separate co-culture sets.
Affymetrix Human GeneChip Arrays were used for
Microarray analysis. Experimental procedures for GeneChip
were performed according to the Affymetrix GeneChip
Expression Analysis Technical Manual. The expression data
was analyzed using the Affymetrix GeneChip Operating
System (Affymetrix) and dChip software [30]. The array data
were also deposited in the GEO (accession number
GSE44458).
Determination of chemokine levels
For the measurement of CCL5 expression 2 x 104 HSC-3,
SAS and DOK cells were cultured as a monoculture or in co-
culture with 2 x 104 BMMSCs or GFs (cell ratio 1:1 to 2:1) on
24-well plates (Costar). Cell culture media was collected 40 h
after cell plating and filtered. The expression of chemokine
CCL5 was determined from cell culture media by Quantikine
CCL5/RANTES Immunoassay (R&D Systems).
Patient samples and clinicopathological data
Archival specimens of 105 OTSCC and ten lymph node
metastases (pN1) from patients, surgically treated at the Oulu
University Hospital between the years 1981-2009, were
retrieved from the Oulu University Hospital, Department of
Pathology, Oulu, Finland. Additional nine patients signed out as
tumor-free lymph nodes (pN0) were retrieved from The Chaim
Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. The
median age of 114 patients was 64 years (range 27-87). The
median follow-up time was 101 months (range 18-298 months)
in the surviving patients (n=53). The median follow-up time for
the study patients was 47 months (range 1-298 months).
Patient survival data was acquired from Statistics Finland and
other relevant data from patient records (Table 1). We could
not retrieve treatment data from three of the patients and
survival data from two of the patients. The retrieval of the
patient data was approved by the local ethics committees and
Finnish National Supervisory Authority for Welfare and Health.
Immunohistochemistry
Immunostaining was performed on all of our OTSCC
samples, which were previously selected to be representative
of the tumour mass in the resected specimens. After a high
temperature antigen retrieval method with citrate buffer for
Table 1. Patient clinical data.
  N %
Age at diagnosis
 <55 yrs 40 35.1
 55-70 yrs 30 26.3
 >70 yrs 44 38.6
Sex
 Male 56 49.1
 Female 58 50.9
Tumour grade
 1 40 35.1
 2 62 54.4
 3 12 10.5
Tumour stage
 1-2 63 55.3
 3-4 51 44.7
Neck lymph nodes
 Negative 79 69.3
 Positive 35 30.7
Neck dissection
 No 16 14.0
 Yes 98 86.0
Adjuvant therapy
 No 68 59.6
 Radiotherapy 34 29.8
 Radio- and chemotherapy 9 7.9
 Missing data 3 2.6
  
Total  114  
doi: 10.1371/journal.pone.0077692.t001
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CCL5 (REAL Target Retrieval Solution, pH 6; Dako, Glostrup,
Denmark) or Tris/EDTA for PINP (10 mmol/L Tris, 1 mmol/L
EDTA, pH 9), sections were blocked by incubation with normal
goat serum for 30 min. Slides were incubated overnight at 4°C
with the polyclonal goat anti-human CCL5 antibody (#AF-278-
NA, R&D Systems) at a 1:100 dilution. For the polyclonal rabbit
anti-human antibody PINP [31] slides were incubated for one
hour at room temperature with the PINP primary antibody at a
1:5000 dilution. Samples were incubated with secondary
antibodies specific for each species. For detection we used
Dako EnVision kit (Dako) with Diaminobenzidine (Dako basic
DAB-kit) as a chromogen. Counterstaining was done in the
Dako Autostainer (Dako, Copenhagen, Denmark). In negative
controls IgG of each respective species was used instead of
primary antibody.
Immunohistochemical assessment of PINP and CCL5
expression
Expression of PINP and CCL5 was evaluated through
immunohistochemistry. Samples were analyzed by three
independent researchers (K.M., J.H.K., and T.S. or S.S.,
J.H.K., and T.S.; lymph nodes free of metastatic disease were
examined by D.D. and M.V.). Different patterns of classifying
expression were chosen. At first samples were classified based
on the overall difference of staining between the superficial and
invasive areas of the tumors were categorized (staining
appears more intensive in superficial areas of the tumor or
staining appears more intensive in invasive areas of the tumor).
The percentage of positive cells in the stromal and tumor cells
in both the superficial and invasive areas of the tumor was
scored on a four point scale (0 = 0%, 1 = 0-25%, 2 = 25-50%
and 3 = >50%, titled no, low, moderate and high expression,
accordingly). Additionally, the presence of PINP staining in
blood and lymphatic vessels was assessed. The subepithelial
stroma of morphologically normal epithelium was also stained.
At dysplastic mucosa sites both epithelial cells and the
subepithelial stromal cells were analyzed.
RNA Interference
Three commercial CCR5 short hairpin RNA (shRNA)
oligonucleotides (Thermo Scientific #VGH5518-98903425,
#VGH5518-99159618, #VGH5518-99294601) and non-
silencing control (Thermo Scientific #RHS4348) were obtained
from Thermo Scientific Open Biosystems GIPZ Lentiviral
shRNAmir Library (Thermo Scientific). The transductions of
HSC-3 cells with viral and control vectors were performed
according to manufacturer’s instructions with puromycin
(Sigma-Aldrich) selection. The efficiency of knockdown by
CCR5-shRNA was determined by flow cytometric analysis
using monoclonal anti-CCR5 antibody (BD Pharmingen,
#556903) and isotype matched IgG (BD Pharmingen, #555576)
as a control. About 70 % knockdown of CCR5 was obtained
compared to non-silencing control cells with one of the
commercial oligonucleotides (Thermo Scientific
#VGH5518-99159618).
Statistical analysis
All assays were repeated 2 - 4 times, except the 3D invasion
assay with SAS and DOK cells that was performed only once
with triplicate myoma disks per mono- or co-culture.
Differences in cell proliferation and wound healing, invasion
area and depth were evaluated by using Student’s t-test. In all
experiments, a p-value of less than 0.05 was considered
statistically significant. For statistical analyses of the patient
material we used PASW Statistics 18 (IBM corp.) software. A
chi-square-test was used to calculate statistically significant
differences between prognostic and clinicopathological
variables. Survival tables were calculated according to the
Kaplan-Meier method, and were compared with the log-rank
test. Multivariate survival and recurrence analyses were done
with the Cox proportional hazards model using the following
covariates: gender (male or female), age at the time of
diagnosis (<55 yrs, 55-70 yrs and >70 yrs), tumour stage (1–4)
and tumour histologic grade (well =1, moderately = 2 and
poorly = 3 differentiated carcinomas according to World Health
Organization head and neck carcinoma classification (2005)
together with PINP expression pattern variables as indicated.
Cox regression was done using backward stepwise selection of
variables, and a p value of 0.05 was adopted as the limit for
inclusion of a covariate.
Results
BMMSCs induce tongue cancer cell invasion in the 3D
in vitro organotypic model
The effect of BMMSCs on tongue cancer cell invasion was
examined in the myoma organotypic model [29] that is more
faithful to the human TME than previous animal tissue derived
models. Human tongue carcinoma cells, HSC-3, SAS or
dysplastic DOK cells were cultured as a monoculture or in co-
culture with BMMSCs on the top of myoma disks. After 10 - 14
days invasion area and depth were quantitated by analyzing
images taken from pancytokeratin stained histological sections
from monoculture and co-culture disks. As shown in Figure 1,
BMMSCs induced an increase in invasion area, and even a
clearer effect was seen on the invasion depth in HSC-3-
BMMSCs co-cultures (Figure 1A-1B). A slight increase in the
invasion area was seen also with SAS cells in the presence of
BMMSCs, although not statistically significant. However, there
seemed to be no effect on invasion depth (Figure 1C-1D).
Interestingly, BMMSCs inhibited the invasion of dysplastic DOK
cells (Figure 1D-1E) suggesting a different effect of BMMSCs
on carcinoma cells compared to non-malignant cells.
To study if the increased invasion of HSC-3 cells was due to
increased cell proliferation, HSC-3 and SAS cells were cultured
on top of myoma disk as a monoculture or co-culture with
BMMSCs or GFs. Histological sections obtained from these
disks were immunostained with the proliferation marker Ki67
and positive cells were calculated as described in Materials
and Methods. Cell proliferation levels were remarkably lower in
HSC-3 and SAS co-cultures with BMMSCs as compared to co-
cultures with GFs (Figure 2A-2B). To confirm that the effect
seen in histological sections came from the reduced
proliferation of cancer cells, HSC-3 cells were cultured as a
Mesenchymal Stem Cells in Oral Tongue Carcinoma
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mono- or co-culture on cell culture chamber slides with
BMMSCs labeled with a fluorescent dye. After co-culture
overnight, cells were stained for Ki67. As shown in Figure 2C,
BMMSCs inhibited HSC-3 cell proliferation significantly also in
the cell co-culture assay. The viability of HSC cells remained
still high and no sign of apoptosis was detected (data not
shown).
As proliferation was not increased, to evaluate if the
increased invasion was a consequence of a higher cancer cell
migration a scratch assay was performed with HSC-3 and DOK
cells seeded alone or together with BMMSCs or GFs to 24-well
plates. BMMSCs shifted HSC-3 cells, but not dysplastic DOK
cells, towards a migratory phenotype with lamellipodia
structures and less cell-cell contacts (Figure 2D). However,
GFs promoted faster wound closure than BMMSCs, which may
be partly due to effects of serum on the proliferation capacity of
cancer cells (Figure 2D-2E)
The expression of chemokine CCL5 is up-regulated in
BMMSCs after interaction with cancer cells
BMMSCs were then cultured with conditioned media
obtained from HSC-3. Although several genes were up-
regulated, the highest increase in gene expression in BMMSCs
was seen in chemokine genes (Table 2). When the chemokine
expression was examined at protein level the expression of
CCL5 was found to be primarily a result of the interaction
between HSC-3 and BMMSC cells rather than from the co-
cultures of HSC-3 cells and GFs (Figure 3A). Similar findings
were obtained from co-cultures of SAS and BMMSCs, but not
from DOK cells interacting with BMMSCs (Figure 3A). At
protein level, the up-regulation of most of the chemokines listed
on the Table 2 was found to originate from OTSCC cell lines
interactions with both BMMSCs and GFs. Some chemokines,
such as CCL2, CCL20 and CXCL8, were also up-regulated as
a result of interactions between BMMSCs and DOK cells, as
studied in immunoassays (data not shown).
Figure 1.  BMMSCs enhance tongue cancer cell invasion in 3D organotypic model.  Bone marrow-derived BMMSCs enhance
the invasion of HSC-3 cells (A, B), but not dysplastic cells (E, F) in 3D myoma organotypic model [29]. Minor increase, although not
statistically significant, was seen in the invasion area of SAS (C,D). Histological sections obtained from myoma disks were stained
with monoclonal pancytokeratin antibody (DAKO, clone AE1/AE3) and photographed at 100 x magnifications with a DMRB photo
microscope connected to DFC 480 camera using QWin V3 software (Leica Microsystems). Scale bar 100 µm.
doi: 10.1371/journal.pone.0077692.g001
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Figure 2.  BMMSCs inhibit cell proliferation in tongue cancer cells.  Histological sections obtained from myoma disks were
stained with polyclonal anti-Ki67 antibody. BMMSCs inhibit proliferation of HSC-3 and SAS cells in organotypic invasion model (A,
B) as well as in cell culture assays (C), and shift HSC-3, but not dysplastic DOK cells towards a migratory phenotype with less cell-
cell contacts (D, arrowheads). Normal gingival fibroblasts, GFs, promote wound closure more than BMMSCs potentially partly due
to the increase in cell proliferation of cancer cells (E). Scale bar 50 µm.
doi: 10.1371/journal.pone.0077692.g002
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Function-blocking antibody against CCL5 inhibits
BMMSC increased invasion area
We next explored the importance of CCL5 in the spread of
tongue cancer, since CCL5 has been shown to promote the
motility of oral cancer cells [32]. CCL5 was also shown to be
important in tumor progression of several cancers, such as
breast and colorectal carcinoma [17,33]. Therefore, we tested
the effect of CCL5 function-blocking antibody on OTSCC and
BMMSC co-cultures in the 3D invasion model. We also tested
the potential effect of function blocking antibody against CXCL1
on invasion, since CXCL1 was also expressed from BMMSC-
HSC-3 interaction and it has previously been demonstrated to
be present in cancers including breast, lung, colorectal and
prostate cancers either supporting or suppressing tumor
progression [34–36]. In oral cancer CXCL1 has been
suggested to have a role in tumor progression since in patient
samples the expression of CXCL1 has been shown be
associated with leukocyte infiltration, lymph node metastasis,
and angiogenesis [37]. As shown in Figure 3, the CCL5
function–blocking monoclonal antibody was able to significantly
attenuate BMMSC-promoted HSC-3 cell invasion area, but had
no effect on invasion depth (Figure 3B-3C). CXCL1 did not
have an effect on invasion as it did not increase the inhibitory
effect of CCL5 in the 3D invasion model (Figure 3B-3C).
In patient samples CCL5 is expressed mainly by
inflammatory cells and some cancer cells, but only
sparse CAFs are CCL5 positive
Next, to evaluate the importance of CCL5 expression in
patient tumor samples for diagnostics of tongue cancer,
histological sections representing different stages of dysplastic
lesions and tongue carcinomas from human patients were
stained with anti-CCL5 antibody. The expression of CCL5 was
mostly detected in inflammatory cells and in some cancer cells
(Figure 4A-4B), but only sparse CAFs were CCL5 positive, as
assessed by immunohistochemical co-localization of CCL5 and
CAF marker αSMA (data not shown). However, the expression
of CCL5 was not associated with the clinical outcome of the
OTSCC patients (not shown). The expression of CCL5 was
further studied in normal primary oral fibroblasts (NOF, [28])
Table 2. Up-regulated chemokine genes in BMMSCs after
exposing to conditioned HSC-3 cell culture media (fold
change > 2).
Gene Symbol Fold Change
chemokine (C-C motif) ligand 2 CCL2 830.66
chemokine (C-C motif) ligand 5 CCL5 194.90
chemokine (C-C motif) ligand 20 CCL20 182.23
chemokine (C-X-C motif) ligand 1 CXCL1 134.91
chemokine (C-X-C motif) ligand 2 CXCL2 80.98
chemokine (C-X-C motif) ligand 3 CXCL3 80.14
chemokine (C-X-C motif) ligand 5 CXCL5 73.90
chemokine (C-X-C motif) ligand 8 (interleukin 8) CXCL8 (IL8) 18.06
chemokine (C-C motif) ligand 13 CXCL13 16.86
doi: 10.1371/journal.pone.0077692.t002
and CaDEC12 cells [11]. Immunoassay detecting secreted
CCL5 in cell culture media showed very low or no CCL5
expression in normal fibroblasts, but considerable higher
expression in CaDEC12 cells (Figure 4C).
The role of CCL5/CCR5 axis is not critical in BMMSC
increased tongue cancer invasion
The CCL5 signaling in cancer cells has been proposed to be
mediated mainly, but not necessary exclusively, via CCR5
receptor [38]. Both HSC-3 and SAS cells were shown to
express this receptor (Figure 5A). In co-culture roughly all
cancer cells expressed CCR5, however, in monocultures
approximately only 25 % of cancer cells were positive for
CCR5 suggesting that a contact with stromal cells or CCL5
induction is needed for higher CCR5 expression (flow
cytometry analysis, data not shown). The association of CCL5
and CCR5 expression has been proposed recently also by
others [39,40]. As the CCL5-CCR5 axis has been shown to
promote the motility of human oral cancer cells in vitro [32] and
to induce the expression of MMP9 [32], we also examined the
effect of rCCL5 on MMP9 expression levels in HSC-3 and SAS
as well as in dysplastic DOK cells. Similarly to previous
observation by Chung and co-workers [32] rCCL5 clearly
increased the expression of MMP9 in HSC-3 cells and SAS
cells, but not in dysplastic DOK cells (Figure 5B). However,
rCCL5 did not induce epithelial-mesenchymal transition (EMT)
as analyzed by Western blotting with anti-vimentin antibody, or
proliferation of cancer cells (data not shown).
To explore the importance of CCL5/CCR5 axis in the spread
of tongue cancer, we performed a 3D invasion study with SAS
and HSC-3 OTSCC cells with reduced CCR5 expression and
with function-blocking antibody against CCL5. First, we
inhibited the expression of CCR5 by transducing HSC-3 cells
with CCR5-shRNA and produced a stable cell line with ~70 %
inhibition of CCR5 expression and reduced response to rCCL5
induction (Figure 5C, 5D). In the 3D co-culture invasion assay
the CCR5 knockdown cells invaded equally or than the wild-
type or control HSC-3 cells transduced with non-silencing
shRNA (Figure 5E, 5F). Similar results were also obtained with
a monoclonal antibody against CCR5 (data not shown).
Expression of collagen and epithelial plasticity
components are induced in cancer cells after BMMSC
interaction
Potential mechanisms of the invasion promoting effect of
BMMSCs on cancer cells were further studied by microarray
analysis. HSC-3 cells were used for the experiments, since
they responded more clearly to BMMSCs than SAS cells,
especially in the 3D invasion model. HSC-3 cells were cultured
as a monoculture or co-culture with BMMSC cells on 6-well
plates for 24 h after which HSC-3 cells were sorted out from
co-cultures with FACS (not shown) and RNA was extracted for
microarray analysis. The overall gene profile of HSC-3 cells
after interaction with BMMSCs showed up-regulated gene
expression of ECM components, with the highest induction
occurring for type I collagen mRNA expression. In addition to
various collagens, BMMSC interaction with HSC-3 cells has
also up-regulated modulators of ECM, such as lysyl oxidase
Mesenchymal Stem Cells in Oral Tongue Carcinoma
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Figure 3.  The expression of chemokine CCL5 is up-regulated in co-cultures of BMMSCs cells and OTSCC.  Co-culture of
OTSCC cells with BMMSCs results in the high expression of chemokine CCL5 in HSC-3 and SAS cells, but not in dysplastic DOK
cells (A). Function-blocking monoclonal antibody against CCL5 (Mab CCL5) slightly inhibits BMMSC enhanced invasion area, but
has no effect on the invasion depth, whereas the antibody against CXCL1 does not increase the inhibitory effect in OTSCC invasion
(B, C).
doi: 10.1371/journal.pone.0077692.g003
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(LOX) and other markers of epithelial plasticity, such as
cadherin-11. Molecules associated with cell motility and cancer
invasion, such as α-actinin-4 mRNAs, were also induced in
HSC-3 cells by the interaction with BMMSCs (Table 3).
Type I procollagen is highly expressed in the invasion
front in tumor samples obtained from oral tongue
cancer patients and correlated with worse prognosis
To further evaluate the relevance of type collagen I
expression originating from the cancer cell-stromal interactions
to the aggressiveness of OTSCC, we performed
immunohistochemistry for type I procollagen fragment (PINP).
PINP has previously been shown to be associated with clinical
outcome in breast and ovarian cancers, but so far has never
been shown in OTSCCs [22-24,31]. In our 114 OTSCC cases,
PINP was not found in epithelial cells in histologically normal
nor dysplastic peritumoral tissue (Figure 6A-6B). In some
tumors PINP was almost absent (Figure 6F), however, most of
the cases showed high expression by both carcinoma and TME
cells (Figure 6E, 6G, 6H). In general overview, PINP
expression was more intense either in more invasive or
superficial areas of the tumor (Figure 6C-D). Similar to the
pattern of expression found in the primary tumors, PINP was
also expressed in OTSCC lymph node metastases (Figure 6I).
Furthermore, in a couple of lymph nodes originally signed out
as free of metastases (pN0), PINP was expressed in a cluster
of cells revealing previously unrecognized occult carcinoma
metastases which also stained positive for pancytokeratin (not
shown). We then compared the pattern of PINP expression and
patient clinical data. In our survival analyses, there was a
correlation between worse prognosis and expression of PINP
by OTSCC cells at invasive areas (p=0.018) (Figure 7A).
Increased PINP expression by both carcinoma and stromal
cells at the invasive areas was also correlated to worse
prognosis (p=0.004) (Figure 7B). Both the high expression of
PINP in SCC cells (HR 1.728 95% CI [1.072 - 2.910]) as well
as increased PINP expression by both carcinoma and stromal
cells (HR 1.924, 95% CI [1.127 - 3.285]) at invasive areas were
identified as independent indicators of overall survival along
with patient age and high tumor stage.
Discussion
We studied here the role of bone marrow-derived BMMSCs
in tongue cancer, which had not yet been previously
addressed. We could demonstrate that BMMSCs enhanced the
aggressiveness of OTSCC cells by inducing their invasion
Figure 4.  CCL5 expression in OTSCC patient samples.  CCL5 is mainly expressed by inflammatory cells in TME and some
cancer cells in patient samples as shown by immunostaining with Pab CCL5, but only sparse CAFs are positive for CCL5 (A, B).
CaDEC12 cells, the primary cultures of CAFs obtained from tongue cancer patients, express relative amount of CCL5 compared to
NOFs, normal oral fibroblasts (C). Scale bar 100 µm.
doi: 10.1371/journal.pone.0077692.g004
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Figure 5.  Signaling via CCL5/CCR5 is not critical in OTSCC invasion.  The CCL5 receptor CCR5 is expressed in HSC-3 and
SAS cells, but not in BMMSCs (A). rCCL5 can induce the expression of MMP9 in HSC-3 and SAS, but not in DOK cells (B). The
silencing of the expression of CCR5 receptor in HSC-3 cells downregulates the gene expression about 70 % compared to control
cells and blocks the signaling increasing the expression of MMP9 in cancer cells (C, D). CCR5 knockdown have minor or no effect
on BMMSC enhanced invasion of HSC-3 cells in 3D organotypic model (E, F).
doi: 10.1371/journal.pone.0077692.g005
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capacity, while reducing their proliferation levels. BMMSCs
increased the expression of various chemokines, particularly
CCL5, after interaction with HSC-3 cells. However, interference
of CCL5 inhibited only the invasion area in our complex
organotypic invasion assay. On the other hand, the interaction
between cancer and bone marrow derived cells increased
particularly the expression of type I collagen by carcinoma
cells. The in vivo results derived from OTSCC patients´
samples showed that type I procollagen (PINP) antibody
detected not only stromal mesenchymal cells, as expected, but
interestingly also some of the OTSCC carcinoma cells,
confirming our in vitro findings. Surrounding normal epithelial
cells were negative for PINP staining. Importantly, the high
expression of PINP in invasive areas of cancer correlated with
the mortality of the patients. We speculate that the molecular
cross-talk between BMMSCs and carcinoma cells leads to
invasion promoting TME changes in OTSCC of which PINP,
but not CCL5, could be used as prognostic marker for the
OTSCC prognosis. In addition, the presence of PINP
expression in cells within metastatic lymph nodes suggests the
involvement of PINP also in the metastatic spread of the
OTSCC.
Table 3. Microarray analysis of up-regulated genes in
HSC-3 cells after interacting with BMMSCs.
Gene Symbol Fold Change
collagen, type I, alpha 2 COL1A2 161.55
lumican LUM 82.13
collagen, type I, alpha 1 COL1A1 67.11
periostin, osteoblast specific factor POSTN 43.08
fibrillin 1 (Marfan syndrome) FBN1 30.94
gremlin 1 homolog, cysteine knot superfamily
(Xenopus laevis) GREM1 30.83
collagen, type VI, alpha 3 COL6A3 30.28
platelet-derived growth factor receptor, beta
polypeptide PDGFRB 22.38
gap junction protein, alpha 1, 43kDa (connexin 43) GJA1 21.12
collagen, type III, alpha 1 (Ehlers-Danlos syndrome
type IV, autosomal dominant) COL3A1 17.78
ABI gene family, member 3 (NESH) binding protein ABI3BP 13.92
transgelin TAGLN 5.61
chromosome 5 open reading frame 13 C5orf13 5.30
chondroitin sulfate proteoglycan 2 (versican) CSPG2 4.38
serine (or cysteine) proteinase inhibitor, clade E
(nexin, plasminogen activator inhibitor type 1),
member 2
SERPINE2 4.26
angiopoietin-like 4 ANGPTL4 4.06
lysyl oxidase LOX 3.67
collagen, type V, alpha 2 COL5A2 3.25
nicotinamide N-methyltransferase NNMT 2.76
prostaglandin-endoperoxide synthase 2
(prostaglandin G/H synthase and cyclooxygenase) PTGS1 2.47
heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 2.41
cadherin 11, type 2, OB-cadherin (osteoblast) CDH11 2.33
actinin, alpha 4 ACTN4 2.1
doi: 10.1371/journal.pone.0077692.t003
We wished to examine the invasion of aggressive tongue
cancer cells using our 3D organotypic model [29] since this
model represents a fully human, hypoxic tumor
microenvironment [29], [41]. It is ideal for the studies of the
early steps of invasion of tongue cancer, since it represents
more faithfully the structure and composition of human ECM in
tumors than the traditional invasion models, based on rat tail
type I collagen and mouse EHS tumor derived Matrigel. We
showed that in co-cultures, BMMSCs stimulated the
dissemination of cancer cells and increased the depth of
invasion, thus enhancing the aggressiveness of tongue cancer
cells. Several studies have demonstrated the invasion and
metastasis promoting role of BMMSCs in various cancers, such
as breast, colon and lymphatic cancers [17], [18], [19].
However, the effect of BMMSCs on different tumor cells has
remained controversial, potentially because of the different
models and sources of BMMSCs used. Also, there may be
differences in the responses of cancer cells and cancer
subtypes to BMMSCs [20], [21]. In our experiments, we used
two invasive tongue cancer cell lines and found that HSC-3, the
most aggressive one, responded more efficiently to signals
originating from BMMSCs in the 3D invasion model. However,
in monolayer cell culture assays both OTSCC cell lines
responded similarly to the BMMSC interactions. Differences in
the responses in the 3D assays may partially be explained by
different genetic background of these cells or by the transient
effect of BMMSCs during the early steps of invasion similarly to
breast cancer [17]. This transient effect is potentially difficult to
see with the fairly aggressive cancer cells in the time-frame
used in our 3D assays. In our study, BMMSCs were not able to
induce an invasive phenotype in dysplastic DOK cells,
suggesting differences in the capacity of invasive and non-
invasive cells to respond to signals originating from BMMSCs.
This also could reflect the EMT –process in which
mesenchymal-like cells are more responsive to mesenchymal
signaling.
The roles of chemokines and their receptors in tongue
cancer progression are not fully understood. Here we showed
that BMMSCs increased the expression of various chemokines,
including CCL5. This effect was more intense in the interaction
between BMMSCs and tongue cancer cells than between
normal fibroblasts and cancer cells. The neutralization of CCL5
activity with a function-blocking monoclonal antibody resulted in
the inhibition of invasion area, but had no effect on invasion
depth. This suggests that CCL5 might affect more the number
of superficially disseminating invasive cells than the total
invasive capacity of tongue carcinoma cells. In patient
samples, however, the CCL5 expression was mainly detected
in inflammatory cells in TME, some cancer cells and some
sparse CAFs. BMMSCs have been shown to be one source of
CAFs in TME [12,14]. Although we did not examine in detail the
differentiation capacity of BMMSC, e.g. into CAFs when
interacting with tongue cancer cells, our preliminary results
from qt-RT-PCR analysis and immunostainings showed a clear
increase in the gene expression of CAF-marker αSMA after the
exposure of BMMSC to cancer cell culture media and more
αSMA-positive BMMSCs in co-cultures with cancer cells than in
BMMSC mono-culture (not shown). However, similarly to the
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results from other groups [20] we also detected the variability of
the different batches of patient BMMSCs regarding the
expression of αSMA, even though cell populations with low
passage numbers were used. It remains to be shown if the
effects seen in this study originate from BMMSCs or from
BMMSCs differentiated to CAFs.
The invasion and metastasis promoting effect of BMMSCs
on breast cancer cells has been proposed to be essential and
dependent on the CCL5-CCR5 axis [17,32,42]. In addition,
antibodies against CCL5 have been shown to reduce the
metastatic index in breast cancer [17] and CCR5 antagonists
have been demonstrated to block metastasis of basal breast
cancer cells [39]. CCL5/CCR5 axis has also been proposed to
affect the motility of human osteosarcoma [40] and oral cancer
cells in vitro [32] and CCL5 neutralization was shown to restrict
tumor progression in colorectal carcinoma [33]. In tongue
cancer the CCL5/CCR5 axis stimulated increased cell
migration and the expression of MMP9 has been proposed to
be mediated through NF-kappaB signaling pathways [32].
Although HSC-3 cells expressed CCR5 and recombinant CCL5
induced MMP9 expression through this receptor, the
elimination of CCR5 activity with RNA interference or antibody
against CCR5, and the reduction of MMP9 expression did not
inhibit invasion in 3D invasion assay. MMP9 expressed here by
Figure 6.  OTSCC samples show staining for type I collagen N-terminal propeptide (PINP).  The expression of PINP was not
found in any histologically normal epithelial cells of the carcinoma sections, except in a few of the mesenchymal cells within wound
bed (arrow heads). The wound epithelial border is marked by dotted line (A). PINP expression was not found in dysplastic
epithelium but was present in a few spindle cells in the submucosa (B). In various cases PINP expression was more intense in
either superficial (C) or invasive (D) areas (arrow heads). Some cancers were mainly negative for PINP staining with a few sporatic
positive areas (F), whereas other cases showed intense staining for both cancer and mesenchymal cells (E). In a couple of cases
PINP was expressed in the periferal cells of invading islands (G) or mainly in the spindle carcinoma associated mesenchymal cells
(H). Lymph node metastases were occasionally positive for PINP (I). Scale bar 200µm .
doi: 10.1371/journal.pone.0077692.g006
Mesenchymal Stem Cells in Oral Tongue Carcinoma
PLOS ONE | www.plosone.org 12 October 2013 | Volume 8 | Issue 10 | e77692
this aggressive oral tongue HSC-3 cell line may only be of
minor importance, since its expression was not significantly
increased in cancer cells after BMMSC interaction based on
the microarray analysis (Table 3). Instead, MMP in the
BMMSCs [43] could be of importance in the regulation of the
ECM proteins. The result also suggests compensatory
utilization of other signaling pathways for CCL5, such as via
CCR1 or CCR3 receptors, thus blocking only one signaling
route may not be efficient enough to inhibit invasion in complex
assays, such as 3D myoma organotypic model.
The interaction with BMMSCs has particularly increased the
expression of ECM proteins in tongue cancer cells.
Interestingly, the highest induction occurred for type I collagen
mRNA. Along with this finding, a paper has shown that fibrosis
with type I collagen enrichment at the metastatic site can
trigger the dormant-to-proliferative switch in dormant tumor
cells leading to metastatic disease [44]. Recently, Shen and
colleagues showed that fibrillar type I collagen is important in
affecting the invasion of aggressive ovarian cancer cells [45]
and Nguyen-Ngoc et al. demonstrated metastatic mammary
tumors to preferentially disseminate in specific ECM
microenvironment containing also type I collagen [46]. More
interestingly, transcriptomic dissection of OTSCC patient
samples has revealed enhancements in e.g. ECM organization
and biogenesis, and collagen catabolism. Type I collagen was
one of the up-regulated genes in the signature gene sets for
OTSCC [47]. In addition, modulation of molecules associated
to cell motility and cancer invasion, for example, the down-
regulation of α-actinin-4, has recently been shown to decrease
invasion potential in oral squamous cell carcinoma [48].
Although in our OTSCC cells there were no remarkable
changes in the gene expression of traditional EMT markers
[49], after the interaction with BMMSCs, up-regulation in the
expression of EMT plasticity biomarkers, such as cadherin-11,
was detected. We speculate that the increase in the expression
of all these components may indicate invasion promoting
changes in the extracellular vicinity of cancer cells. However,
more studies are needed to clarify these observations at
cellular level.
Our OTSCC patient samples showed that PINP antigen,
representing the procollagen fragment of type I collagen, was
present not only in stromal cells, as expected, but also in
OTSCC carcinoma cells and in lymph node metastases. Thus,
the results supported the above mentioned in vitro observation
demonstrating the increase of type I collagen expression in
cancer cells that interact with stromal cells, including BMMSCs.
So far, PINP expression has not been described in OTSCCs.
However, the fibroproliferative TME response, or desmoplastic
Figure 7.  Survival analyses for PINP expression.  In our set of samples, high PINP expression (PINP >50 %; n=41, 27 deaths in
the group) compared to low expression (PINP 0-50%, n=71, 32 deaths) in OTSCC cells at the invasive front (>50%) correlated with
increased overall deaths (A). In general overview, the increased expression of PINP in both OTSCC and stromal cells in the
invasive areas of the tumor was observed in 76 patients (35 deaths in the group), whereas increased expression of PINP in
superficial areas was observed in 36 patients (24 deaths). The higher expression of PINP in invasive areas associated with worse
prognosis, p=0.004 (B).
doi: 10.1371/journal.pone.0077692.g007
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reaction, has already been reported as a prognostic predictor
of occult metastasis in OTSCCs [50]. The similarity between
desmoplastic reactions in cancer stroma and wound healing
are evident in type I collagen processes [51]. PINP has been
demonstrated to be a prognostic marker in primary and
secondary brain tumors [52] and breast cancer [52] as well as
osteosarcoma cells, osteoblasts and proliferating fibroblasts
[53,54]. Our results proved that the high PINP expression at
the invasive front serves as a reliable indicator for aggressive
growth and metastases and could be useful as a prognostic
marker also in OTSCCs.
To conclude, BMMSCs promoted the invasion of tongue
carcinoma cells by inducing the expression of components
associated to chemokine signaling, epithelial plasticity, cell
motility and invasion, potentially promoting invasion favoring
changes in cancer cells and in the TME. Although CCL5
expression was induced in BMMSCs after interaction with
OTSCC cells, signaling through CCL5/CCR5 axis does not
seem to be critical for the BMMSC enhanced cancer invasion.
Instead, the induction of ECM protein production, particularly
type I collagen, by cancer cells after BMMSC interaction turned
out to be more crucial for OTSCC behavior in vitro. Moreover,
based on our clinical data we suggest that PINP antibody,
recognizing type I collagen N-terminal propeptide, is an
appropriate prognostic marker for OTSCC.
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